NCT06037655View on ClinicalTrials.gov

Chemotherapy Combined With Adebrelimab and Mecapegfilgrastim in Neoadjuvant Treatment of Potentially Resectable BTC

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

September 25, 2023

Primary Completion Date

March 31, 2026

Study Completion Date

December 31, 2026

Conditions
Biliary Tract Neoplasms
Interventions
DRUG

Total Neoadjuvant Treatment

Adebrelimab (1200 mg) every three weeks intravenously; Mecapegfilgrastim (6 mg) every three weeks intravenously; Gemcitabine (1000 mg/m2) every three weeks on days 1 and 8 intravenously; Cisplatin (25 mg/m2) every three weeks on days 1 and 8 intravenously

All Listed Sponsors
lead

The First Affiliated Hospital with Nanjing Medical University

OTHER

NCT06037655 - Chemotherapy Combined With Adebrelimab and Mecapegfilgrastim in Neoadjuvant Treatment of Potentially Resectable BTC | Biotech Hunter | Biotech Hunter